In a research report released Thursday, Chardan Capital analyst Gbola Amusa reiterated a Neutral rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), with a price target of $12.50, after the drug maker announced positive top-line results from its eight-week Phase 2 study of bempedoic acid added to atorvastatin which showed a 22% reduction in LDL-C from baseline compared to placebo against a background of atorvastatin in all subjects.

Esperion share are currently trading at $12.84, up $0.52 or 4.22%.

Amusa noted, “We believe these results suggest safety concerns in adding bempedoic acid to high-intensity (high-dose) statins, creating questions on what place in the market there is, if any, for the product, since if the high-intensity statins and statins intolerance markets are ruled out for a label, patients with inadequate LDL-C control on low intensity statins are likely to be put on higher-intensity generic statins or on generic ezetimibe.”

“We believe the rate of adverse events is very troubling, may rule out bempedoic acid use with high intensity statins, and likely still points to the need for outcomes trials for bempedoic acid approval,” the analyst added.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Gbola Amusa MD CFA has a yearly average return of -9.1% and a 39.7% success rate. CFA has a 61.9% average return when recommending ESPR, and is ranked #3986 out of 4182 analysts.

Out of the 12 analysts polled by TipRanks, 6 rate Esperion Therapeutics Buy, 5 rate the stock a Hold and 1 recommends a Sell. With a return potential of 105%, the stock’s consensus target price stands at $26.44.